Sharemaestro company-news research for BeiGene, Ltd. (ONC), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.
NASDAQ
United States
Provisional evidence
Company news sentiment
Latest ONC news and sentiment
BeiGene, Ltd.
Company headlines from the last 30 days, weighted by freshness, relevance, publisher quality and the strength of the wording. Price is shown separately.
Current company news
Early balanced news score
6 company-specific stories are available, but there are not yet enough fresh stories from separate publishers for a firm reading.
Observed headline tone65/100
โ
Published 30-day score51/100
Latest source headline
Truist Financial Maintains BeiGene(ONC.US) With Buy Rating, Announces Target Price $420
Moomoo ยท 09 Oct 2026 05:42
Older, less relevant and less reliable stories count for less. Confidence is shown separately.
What supports the score
6 current stories are mapped specifically to ONC.
The score uses 3 publishers rather than depending on one outlet.
What limits the score
The stories agree, but freshness-weighted evidence is only 0.075.
Confidence is 18/100, below the threshold for a firm score.
51/100
News scoreEarly balanced news score
18/100
Confidencethin evidence
95%/100
Company news6 company stories
88/100
Story agreement12/100 difference
News history
Daily score and story count over 30 days
17 Sep02 Oct16 Oct
News scoreStory count50 baseline
Confidence
How reliable the score is
Confidence uses the amount of news, separate publishers, direct company relevance, freshness and agreement. A high or low score is not automatically reliable.
Amount of evidence2
0.075 after freshness weightingSource breadth60
3 independent publishersCompany relevance95
share tied directly to this companyFreshness18
recency-weighted evidenceAgreement88
how closely stories agreePublisher mix48
less reliance on one publisherPrice and news history
Weekly price and news-score history
Company-specific news is present, but the evidence has not yet earned enough independent, fresh information weight for price confirmation to be treated as a firm signal.
26 completed price weeks16 comparable news-score weeks
One scoring method across the chart.Stored company headlines are recalculated at each weekly point with the current 30-day freshness weighting. Old published snapshots are left unchanged.
17 Apr14 Jul09 Oct
Weekly close, indexedSentiment score
WeekNews scoreCloseWeekly move
09 Oct 202653USD 354.47-1.0%
02 Oct 202652USD 358.07-0.8%
25 Sep 202651USD 360.85+2.9%
18 Sep 202654USD 350.84+1.2%
11 Sep 202659USD 346.51-3.3%
04 Sep 202662USD 358.26-2.3%
28 Aug 202662USD 366.73-2.1%
21 Aug 202655USD 374.47+7.8%
Provisional evidence
News subjects
What is shaping the score
Analyst action732 stories ยท 33%
Market update412 stories ยท 33%
Earnings601 stories ยท 17%
Balance sheet411 stories ยท 17%
Source mix
Where the evidence comes from
Moomoo723 stories ยท 50%
AD HOC NEWS412 stories ยท 33%
Simply Wall Street601 stories ยท 17%
Recurring subjects
Subjects appearing most often
Life Sciences6Financial Markets5Earnings3Finance1
Earlier readings
How the score has changed
Past and present use the same method.Each point recalculates the previous 30 days of stored company headlines with today's scoring rules. The original stored snapshots remain unchanged.
20 Jun50 neutral11 Oct 18:12
ConstructiveBalanced or withheldCautious
Changes in the stored score
Scores are rebuilt from stored headlines with the current 30-day method. Days with no change are collapsed.
| Observed | Score | Move | Confidence | Stories | Status |
|---|---|---|---|---|---|
| 11 Oct 18:12 | 52 | -1 | 23/100 (-4) | 6 (-2) | Provisional |
| 09 Oct 23:59 | 53 | +0 | 27/100 (-2) | 8 (-3) | Provisional |
| 01 Oct 23:59 | 53 | +1 | 29/100 (+2) | 11 (-2) | Provisional |
| 26 Sep 23:59 | 52 | +0 | 27/100 (+1) | 13 (-5) | Provisional |
| 23 Sep 23:59 | 52 | +0 | 26/100 (-1) | 18 (+1) | Provisional |
| 20 Sep 23:59 | 52 | -7 | 27/100 (-5) | 17 (-5) | Provisional |
| 11 Sep 23:59 | 59 | +3 | 32/100 (+4) | 22 (-2) | Provisional |
| 10 Sep 23:59 | 56 | -5 | 28/100 (-4) | 24 (-5) | Provisional |
Evidence behind the direction
What drives this reading?
Shares of weighted directional evidence in 6 retained current headlines. These weights already account for freshness, relevance and publisher limits; they are not additive points of the published score.
Which subjects lean each way
A subject can carry both supportive and cautious news.
SubjectCautious โ 0 โ Constructive
Analyst action2 stories
0.0%67.9%
Balance sheet1 story
16.8%0.0%
Earnings1 story
0.0%14.4%
Market update2 stories
0.9%0.0%
Each side uses the same scale: 0โ67.9% of the retained directional evidence.
Where the influence comes from
68.8%largest publisher shareA concentrated reading can depend heavily on one publisher.
Publisher groups follow the scoring rules. Company disclosures share one group; syndicated stories are consolidated before weighting.
Source headlines
The news behind the score
Only company-specific stories enter this score. The latest 30 days are shown newest first, with newer stories weighted more heavily and duplicate coverage combined.
72/100 tone
Truist Financial has reiterated its Buy rating on BeiGene (ONC.US) and set a price target of $420. This indicates the firm's continued confidence in the pharmaceutical company's stock performance.
59% of directional evidence
Medium story strength
Scoring detailsDirect company coverage
Truist Financial has reiterated its Buy rating on BeiGene (ONC.US) and set a price target of $420. This indicates the firm's continued confidence in the pharmaceutical company's stock performance.
- Published
- 09 Oct 2026 05:42
- News subject
- Analyst action
- Why this score
- Buy Rating
- Company focus
- Main company ยท 100%
- How it is used
- Direct company coverage
- Story strength
- Medium ยท 53/100
- 30-day weight
- 59% of directional evidence ยท 7.2d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
EarningsFinanceLife Sciences
77/100 tone
J.P. Morgan has reiterated its Buy rating for BeiGene (ONC.US) and increased its target price to $445. This positive adjustment by the investment bank reflects continued confidence in the biopharmaceutical company's financial outlook and growth prospects.
8.9% of directional evidence
Medium story strength
Scoring detailsDirect company coverage
J.P. Morgan has reiterated its Buy rating for BeiGene (ONC.US) and increased its target price to $445. This positive adjustment by the investment bank reflects continued confidence in the biopharmaceutical company's financial outlook and growth prospects.
- Published
- 01 Oct 2026 16:27
- News subject
- Analyst action
- Why this score
- Buy Rating
- Company focus
- Shared story ยท 78%
- How it is used
- Direct company coverage
- Story strength
- Medium ยท 50/100
- 30-day weight
- 8.9% of directional evidence ยท 14.7d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
Financial MarketsLife Sciences
40/100 tone
A director at BeiGene (ONC.US) has sold 68,000 shares of common stock for a total of US$11.32 million. This transaction occurred at an average price of US$166.45 per share.
0.9% of directional evidence
Low story strength
Scoring detailsDirect company coverage
A director at BeiGene (ONC.US) has sold 68,000 shares of common stock for a total of US$11.32 million. This transaction occurred at an average price of US$166.45 per share.
- Published
- 01 Oct 2026 00:02
- News subject
- Market update
- Why this score
- Institutional or insider selling
- Company focus
- Main company ยท 100%
- How it is used
- Direct company coverage
- Story strength
- Low ยท 34/100
- 30-day weight
- 0.9% of directional evidence ยท 15.4d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
Financial MarketsLife Sciences
60/100 tone
BeOne Medicines (ONC) has garnered attention following its rebrand from BeiGene, Ltd. in May 2025, maintaining a strong oncology focus. While the company's strong revenue growth and a fair value of $433.02 suggest it is undervalued by 17%, its high P/E ratio of 62.6x, compared to an indusโฆ
14.4% of directional evidence
Medium story strength
Scoring detailsDirect company coverage
BeOne Medicines (ONC) has garnered attention following its rebrand from BeiGene, Ltd. in May 2025, maintaining a strong oncology focus. While the company's strong revenue growth and a fair value of $433.02 suggest it is undervalued by 17%, its high P/E ratio of 62.6x, compared to an industry average of 17.3x, indicates potential valuation risk. The article highlights both the optimistic growth narrative driven by its best-in-class oncology therapies and the risks associated with competition and drug pricing pressures.
- Published
- 26 Sep 2026 15:50
- News subject
- Earnings
- Why this score
- Operating growth, Positive valuation view
- Company focus
- Shared story ยท 78%
- How it is used
- Direct company coverage
- Story strength
- Medium ยท 36/100
- 30-day weight
- 14.4% of directional evidence ยท 19.7d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
EarningsFinancial MarketsLife Sciences
59/100 tone
Market update
BeiGene stock gains 2.16 percent as biotech shares rise
BeiGene stock increased by 2.16 percent in Hong Kong trading on September 22, 2026, as the broader biotechnology sector also saw gains. While this reflects a positive market signal, the article emphasizes that the company's financial performance and operating figures remain the critical mโฆ
<0.1% of directional evidence
Low story strength
Scoring detailsDirect company coverage
BeiGene stock increased by 2.16 percent in Hong Kong trading on September 22, 2026, as the broader biotechnology sector also saw gains. While this reflects a positive market signal, the article emphasizes that the company's financial performance and operating figures remain the critical metrics for investors to assess its valuation, rather than relying solely on sector-driven movements. The gain was noted to be smaller than some other biotech advances on the same day, suggesting a sector-wide uplift rather than a company-specific event.
- Published
- 23 Sep 2026 00:19
- News subject
- Market update
- Why this score
- Positive financial language
- Company focus
- Main company ยท 100%
- How it is used
- Direct company coverage
- Story strength
- Low ยท 31/100
- 30-day weight
- <0.1% of directional evidence ยท 23.4d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
Financial MarketsLife Sciences
41/100 tone
BeiGene Ltd. (BGNE) stock is holding steady despite recent quarterly losses, as investors weigh the company's expanding oncology pipeline against its ongoing cash burn. While revenue continues to grow, operating expenses keep the company in the red, underscoring the long path to profitabiโฆ
16.8% of directional evidence
Medium story strength
Scoring detailsDirect company coverage
BeiGene Ltd. (BGNE) stock is holding steady despite recent quarterly losses, as investors weigh the company's expanding oncology pipeline against its ongoing cash burn. While revenue continues to grow, operating expenses keep the company in the red, underscoring the long path to profitability. Analysts focus on pipeline strength and global partnerships, but also highlight the need for continued funding and the risks associated with clinical development and commercialization.
- Published
- 20 Sep 2026 13:03
- News subject
- Balance sheet
- Why this score
- Negative financial language
- Company focus
- Main company ยท 100%
- How it is used
- Direct company coverage
- Story strength
- Medium ยท 38/100
- 30-day weight
- 16.8% of directional evidence ยท 25.8d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
EarningsFinancial MarketsLife Sciences
Earlier company news
ONC news archive
Stored newest first for historical research. It starts after the newest three pages above and then continues through older news. Each archive page is loaded only when it is opened.
11Sep 2026
ArchivedPositive tone
Barclays Maintains BeiGene(ONC.US) With Buy Rating, Raises Target Price to $415
Barclays has reiterated its Buy rating for BeiGene (ONC.US) and increased its price target from $400 to $415. This adjustment reflects continued confidence in the pharmaceutical company's future performance.
Article detailsHistorical record
Barclays has reiterated its Buy rating for BeiGene (ONC.US) and increased its price target from $400 to $415. This adjustment reflects continued confidence in the pharmaceutical company's future performance.
- Published
- 11 Sep 2026 16:57
- Catalyst
- Analyst action
- Coverage
- Direct company
- Duplicates
- 1 consolidated
FinanceFinancial MarketsLife Sciences
10Sep 2026
ArchivedNegative tone
BeiGene(ONC.US) Director Sells US$13.37 Million in Common Stock
A director at BeiGene (ONC.US) recently sold 100,000 shares of common stock at an average price of $133.7 per share, totaling $13.37 million. This transaction was disclosed in a Form 4 filing with the SEC.
Article detailsHistorical record
A director at BeiGene (ONC.US) recently sold 100,000 shares of common stock at an average price of $133.7 per share, totaling $13.37 million. This transaction was disclosed in a Form 4 filing with the SEC.
- Published
- 10 Sep 2026 21:58
- Catalyst
- Market update
- Coverage
- Direct company
- Duplicates
- 1 consolidated
FinanceFinancial MarketsLife Sciences
06Sep 2026
ArchivedNeutral tone
BeOne Medicines (ONC) Stock May Be Fully Priced After An 86% Run
BeOne Medicines has delivered an 86.0% gain over the past three years, yet current valuation checks point to a stock that screens as overvalued on market multiples and only mixed on broader metrics. Recent regulatory wins and a higher share price leave investors weighing a strong track reโฆ
Article detailsHistorical record
BeOne Medicines has delivered an 86.0% gain over the past three years, yet current valuation checks point to a stock that screens as overvalued on market multiples and only mixed on broader metrics. Recent regulatory wins and a higher share price leave investors weighing a strong track record against a less clear-cut value case. BeOne Medicines is up 86.0% over three years, which makes the stock more dependent on whether the business can now justify that stronger share price profile. FDA approval for the TEVIMBRA regimen in HER2-positive gastroesophageal adenocarcinoma can support expectations
- Published
- 6 Sep 2026 00:06
- Catalyst
- Market update
- Coverage
- Direct company
- Duplicates
- 2 consolidated
Balance SheetBiotechEarningsFda ApprovalHealthcareShare Price
05Sep 2026
BeOne Medicines recently secured U.S. FDA approvals for TEVIMBRA and ZIIHERA-based regimens in first-line HER2-positive gastroesophageal cancers and entered a voluntary agreement with the U.S. government to expand access to its oncology drugs while investing more than US$1.00 billion in Uโฆ
Article detailsHistorical record
BeOne Medicines recently secured U.S. FDA approvals for TEVIMBRA and ZIIHERA-based regimens in first-line HER2-positive gastroesophageal cancers and entered a voluntary agreement with the U.S. government to expand access to its oncology drugs while investing more than US$1.00 billion in U.S. manufacturing. This combination of first-in-class immunotherapy approval and U.S. tariff exemption tied to onshoring commitments reshapes BeOne's positioning in cancer care and its cost base in a key market. We'll now examine how the first-in-class HER2+ gastroesophageal approval may influence BeOne's onco
- Published
- 5 Sep 2026 04:09
- Catalyst
- Deals and strategy
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Cancer CareFda ApprovalImmunotherapyOncologyUS Manufacturing
04Sep 2026
BeOne Medicines AG (NASDAQ:ONC) entered a voluntary agreement with the U.S. government that combines pharmaceutical-tariff protection with commitments on manufacturing, Medicaid participation, and the pricing of future medicines. The agreement gives BeOne Medicines AG (NASDAQ:ONC) an exemโฆ
Article detailsHistorical record
BeOne Medicines AG (NASDAQ:ONC) entered a voluntary agreement with the U.S. government that combines pharmaceutical-tariff protection with commitments on manufacturing, Medicaid participation, and the pricing of future medicines. The agreement gives BeOne Medicines AG (NASDAQ:ONC) an exemption from Section 232 pharmaceutical tariffs while recognizing more than $1 billion of U.S. manufacturing investment, including a $300 million expansion in Hopewell, New Jersey. The exemption is valuable because affected patented pharmaceuticals and ingredients could otherwise face substantial import duties.
- Published
- 4 Sep 2026 19:44
- Catalyst
- Market update
- Coverage
- Direct company
- Duplicates
- 1 consolidated
ManufacturingMedicaidOncologyPharmaceuticalsTariffs
03Sep 2026
ArchivedPositive tone
Beigene Ltd (ONC) Earnings Forecast: Future EPS & Revenue Growth Estimates
Article detailsHistorical record
- Published
- 3 Sep 2026 08:00
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
01Sep 2026
ArchivedPositive tone
BeiGene stock gains on strong mid term profit rebound
Article detailsHistorical record
- Published
- 1 Sep 2026 20:16
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
01Sep 2026
ArchivedPositive tone
FDA Approval Marks A Turning Point For BeOne Medicines (ONC)
On August 25, BeOne Medicines (NASDAQ:ONC) said the FDA approved TEVIMBRA in combination with ZIIHERA and chemotherapy as a first-line treatment for HER2-positive gastroesophageal adenocarcinoma, a hard-to-treat cancer that strikes more than 31,000 Americans a year. The approval rests on โฆ
Article detailsHistorical record
On August 25, BeOne Medicines (NASDAQ:ONC) said the FDA approved TEVIMBRA in combination with ZIIHERA and chemotherapy as a first-line treatment for HER2-positive gastroesophageal adenocarcinoma, a hard-to-treat cancer that strikes more than 31,000 Americans a year. The approval rests on Phase 3 data showing patients lived a median of 26.4 months, more than two years, the longest survival benchmark yet reported for an immunotherapy-based regimen in this setting regardless of a patient's PD-L1 status. For a company already riding hematology momentum, it adds a genuine second growth engine.FDA A
- Published
- 1 Sep 2026 18:01
- Catalyst
- Regulatory and legal
- Coverage
- Direct company
- Duplicates
- 2 consolidated
BiotechClinical TrialsEarningsFda ApprovalNet IncomeOncology
31Aug 2026
ArchivedNeutral tone
BeiGene, Ltd. (NASDAQ: ONC) Share Price, ONC Stock News, ONC Share Price & Updates
Article detailsHistorical record
- Published
- 31 Aug 2026 16:41
- Catalyst
- Market update
- Coverage
- Direct company
- Duplicates
- 1 consolidated
30Aug 2026
ArchivedPositive tone
BeiGene H1 net profit surges 627% as global Zanubrutinib sales top 16.1 billion yuan
BeiGene reported a significant surge in its H1 2026 net profit, increasing by 627% to 3.27 billion yuan, driven by strong global sales of its core product, Zanubrutinib, which reached 16.13 billion yuan. The company also saw increased revenue from Amgen-authorized products and tislelizumaโฆ
Article detailsHistorical record
BeiGene reported a significant surge in its H1 2026 net profit, increasing by 627% to 3.27 billion yuan, driven by strong global sales of its core product, Zanubrutinib, which reached 16.13 billion yuan. The company also saw increased revenue from Amgen-authorized products and tislelizumab, alongside an expansion in gross margin and improved operating efficiency. Furthermore, BeiGene received FDA approval for a new indication for tislelizumab and raised its full-year revenue guidance, expressing strengthened confidence in Zanubrutinib's long-term growth.
- Published
- 30 Aug 2026 21:24
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
EarningsLife Sciences
28Aug 2026
BeiGene reported a significant 386% year-on-year surge in H1 net profit, reaching $240.2 million, primarily driven by strong sales of its BTK inhibitor, Brukinsa. The company's total revenue exceeded $3.2 billion, demonstrating robust performance across its product portfolio. This financiโฆ
Article detailsHistorical record
BeiGene reported a significant 386% year-on-year surge in H1 net profit, reaching $240.2 million, primarily driven by strong sales of its BTK inhibitor, Brukinsa. The company's total revenue exceeded $3.2 billion, demonstrating robust performance across its product portfolio. This financial report highlights BeiGene's continued growth and the successful commercialization of its key oncology treatments.
- Published
- 28 Aug 2026 00:38
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
EarningsLife Sciences
27Aug 2026
Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the "long context," investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in aโฆ
Article detailsHistorical record
Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the "long context," investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades. While many investors like to look for momentum in stocks, this can be very tough to define.
- Published
- 27 Aug 2026 17:00
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Consensus EstimateEarningsEarnings EstimateEstimate RevisionsMomentum InvestingPrice Change
26Aug 2026
ArchivedNeutral tone
Earnings Preview: BeiGene to Report Financial Results Pre-market on August 27
BeiGene (BGNE) is scheduled to release its financial results on August 27 before the market opens. This preview allows investors to anticipate key metrics and insights from the upcoming earnings report.
Article detailsHistorical record
BeiGene (BGNE) is scheduled to release its financial results on August 27 before the market opens. This preview allows investors to anticipate key metrics and insights from the upcoming earnings report.
- Published
- 26 Aug 2026 22:50
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
EarningsLife Sciences
26Aug 2026
ArchivedPositive tone
BeiGene H1 net profit surges 627% as global Zanubrutinib sales top 16.1 billion yuan
Article detailsHistorical record
- Published
- 26 Aug 2026 08:00
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
25Aug 2026
ArchivedPositive tone
RBC Capital Maintains BeiGene(ONC.US) With Buy Rating, Maintains Target Price $450
RBC Capital has reiterated its Buy rating on BeiGene (ONC.US) and maintained its target price at $450. This indicates a continued positive outlook from the firm regarding BeiGene's stock performance.
Article detailsHistorical record
RBC Capital has reiterated its Buy rating on BeiGene (ONC.US) and maintained its target price at $450. This indicates a continued positive outlook from the firm regarding BeiGene's stock performance.
- Published
- 25 Aug 2026 15:12
- Catalyst
- Analyst action
- Coverage
- Direct company
- Duplicates
- 1 consolidated
EarningsFinanceLife Sciences
25Aug 2026
BeOne Medicines Ltd. - Sponsored ADR (ONC) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, ONC's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross." There's a reasonโฆ
Article detailsHistorical record
BeOne Medicines Ltd. - Sponsored ADR (ONC) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, ONC's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross." There's a reason traders love a golden cross -- it's a technical chart pattern that can indicate a bullish breakout is on the horizon. This kind of crossover is formed when a stock's short-term moving average breaks above a longer-term moving average. Typically, a golden cross involves the 50-day and the 200-day moving averag
- Published
- 25 Aug 2026 14:55
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
EarningsGolden CrossTechnical Analysis
20Aug 2026
ArchivedNeutral tone
BeiGene (06160.HK) will release its financial report on August 26.
BeiGene (06160.HK) announced that it will release its interim financial report for the six months ended June 30, 2026, on Monday, August 26, 2026. The announcement will be made after the market close in Hong Kong and before the market opens in the U.S.
Article detailsHistorical record
BeiGene (06160.HK) announced that it will release its interim financial report for the six months ended June 30, 2026, on Monday, August 26, 2026. The announcement will be made after the market close in Hong Kong and before the market opens in the U.S.
- Published
- 20 Aug 2026 05:41
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
EarningsLife Sciences
19Aug 2026
ArchivedPositive tone
Beigene Ltd (ONC) Earnings Forecast: Future EPS & Revenue Growth Estimates
Article detailsHistorical record
- Published
- 19 Aug 2026 08:00
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
15Aug 2026
Two oncology powerhouses, BeOne Medicines AG (NASDAQ:ONC) and Revolution Medicines, Inc. (NASDAQ:RVMD), announced a major multi-part clinical collaboration and regional licensing deal. Under the August 10 agreement, the companies will combine select clinical-stage assets from BeOne with Rโฆ
Article detailsHistorical record
Two oncology powerhouses, BeOne Medicines AG (NASDAQ:ONC) and Revolution Medicines, Inc. (NASDAQ:RVMD), announced a major multi-part clinical collaboration and regional licensing deal. Under the August 10 agreement, the companies will combine select clinical-stage assets from BeOne with Revolution's four clinical-stage RAS(ON) inhibitors to evaluate novel combination therapies for RAS-addicted cancers. Crucially, BeOne acquired exclusive rights to develop and commercialize these four assets across select Asian markets (excluding Japan and South Korea), agreeing to fund and execute a global reg
- Published
- 15 Aug 2026 00:09
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Balance SheetBiotechClinical TrialsEarningsNet IncomeOncology
14Aug 2026
ArchivedPositive tone
Beigene Ltd (ONC) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Beigene Ltd (ONC), detailing its current earnings forecast score, average price target, and analyst ratings. It highlights that the company ranks 129th in the Biotechnology & Medical Research industry with a score of 8.43, and analysts mostlyโฆ
Article detailsHistorical record
This article provides an earnings forecast for Beigene Ltd (ONC), detailing its current earnings forecast score, average price target, and analyst ratings. It highlights that the company ranks 129th in the Biotechnology & Medical Research industry with a score of 8.43, and analysts mostly support a "Buy" trend for its stock. Key financial forecasts include an expected revenue of $1.75 billion for the next quarter and an EPS expectation of $1.83.
- Published
- 14 Aug 2026 19:11
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
EarningsFinancial MarketsLife Sciences
13Aug 2026
ArchivedNeutral tone
BeiGene(ONC.US) Officer Sells US$86.48 Million in Common Stock
This article reports that a BeiGene (ONC.US) officer sold common stock totaling US$86.48 million.
Article detailsHistorical record
This article reports that a BeiGene (ONC.US) officer sold common stock totaling US$86.48 million.
- Published
- 13 Aug 2026 06:10
- Catalyst
- Market update
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Financial Markets
13Aug 2026
This article first appeared on GuruFocus. Total Revenue: $1.7 billion, representing 30% growth year over year. GAAP Earnings per ADS: $2.05, up 144% compared to the prior year. BRUKINSA Global Revenue: Over $1.2 billion, representing 31% year-over-year growth. US BRUKINSA Sales: $893 millโฆ
Article detailsHistorical record
This article first appeared on GuruFocus. Total Revenue: $1.7 billion, representing 30% growth year over year. GAAP Earnings per ADS: $2.05, up 144% compared to the prior year. BRUKINSA Global Revenue: Over $1.2 billion, representing 31% year-over-year growth. US BRUKINSA Sales: $893 million, representing 31% growth. TEVIMBRA Global Sales: $229 million, representing 18% growth versus the prior period. Amgen In-Licensed Portfolio Revenue: $157 million, growing 25% year over year. US Revenue: Approximately $899 million, growing 31% year over year. China Revenue: Approximately $500 million, growi
- Published
- 13 Aug 2026 02:04
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
BIOTECHBiotechCLINICAL-TRIALSClinical TrialsEARNINGSEarnings
12Aug 2026
ArchivedNeutral tone
BeiGene, Ltd. (NASDAQ: ONC) Share Price, ONC Stock News, ONC Share Price & Updates
Article detailsHistorical record
- Published
- 12 Aug 2026 13:51
- Catalyst
- Market update
- Coverage
- Direct company
- Duplicates
- 1 consolidated
12Aug 2026
ArchivedNeutral tone
BeOne Medicines (ONC) Q2 2026 Earnings Call Transcript
This article first appeared on GuruFocus. Total Revenue: $1.7 billion, representing 30% growth year over year. GAAP Earnings per ADS: $2.05, up 144% compared to the prior year. BRUKINSA Global Revenue: Over $1.2 billion, representing 31% year-over-year growth. US BRUKINSA Sales: $893 millโฆ
Article detailsHistorical record
This article first appeared on GuruFocus. Total Revenue: $1.7 billion, representing 30% growth year over year. GAAP Earnings per ADS: $2.05, up 144% compared to the prior year. BRUKINSA Global Revenue: Over $1.2 billion, representing 31% year-over-year growth. US BRUKINSA Sales: $893 million, representing 31% growth. TEVIMBRA Global Sales: $229 million, representing 18% growth versus the prior period. Amgen In-Licensed Portfolio Revenue: $157 million, growing 25% year over year. US Revenue: Approximately $899 million, growing 31% year over year. China Revenue: Approximately $500 million, growi
- Published
- 12 Aug 2026 08:00
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
BIOTECHBiotechCLINICAL-TRIALSClinical TrialsEARNINGSEarnings
11Aug 2026
ArchivedNeutral tone
BeiGene, Ltd. (NASDAQ: ONC) Share Price, ONC Stock News, ONC Share Price & Updates
Article detailsHistorical record
- Published
- 11 Aug 2026 21:00
- Catalyst
- Market update
- Coverage
- Direct company
- Duplicates
- 1 consolidated
10Aug 2026
BOCOM International has maintained its 'Buy' rating for BeiGene, increasing the target price to HK$276. This reflects a positive outlook on the biopharmaceutical company's future performance and valuation.
Article detailsHistorical record
BOCOM International has maintained its 'Buy' rating for BeiGene, increasing the target price to HK$276. This reflects a positive outlook on the biopharmaceutical company's future performance and valuation.
- Published
- 10 Aug 2026 16:40
- Catalyst
- Analyst action
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Financial MarketsLife Sciences
08Aug 2026
ArchivedNeutral tone
BeiGene Ltd (49BA.DU) stock price, news, quote and history
This article provides detailed financial information for BeiGene Ltd (49BA.DU), including its current stock price, recent performance metrics, key statistics, and historical data. As of August 7th, 2026, the stock closed at 298.00 EUR, up 5.67%, with a market capitalization of 35.92 billiโฆ
Article detailsHistorical record
This article provides detailed financial information for BeiGene Ltd (49BA.DU), including its current stock price, recent performance metrics, key statistics, and historical data. As of August 7th, 2026, the stock closed at 298.00 EUR, up 5.67%, with a market capitalization of 35.92 billion EUR. The page also features comparison tools with other biotechnology companies and market indices.
- Published
- 8 Aug 2026 20:39
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
EarningsFinanceFinancial MarketsLife Sciences
08Aug 2026
ArchivedNeutral tone
BeiGene Ltd (49BA.DU) stock price, news, quote and history
This Yahoo Finance page provides comprehensive financial information for BeiGene Ltd (49BA.DU), including its current stock price, historical data, charts, key statistics, and performance overview. The stock is currently trading at 304.00 EUR, up 2.01%, with detailed valuation measures anโฆ
Article detailsHistorical record
This Yahoo Finance page provides comprehensive financial information for BeiGene Ltd (49BA.DU), including its current stock price, historical data, charts, key statistics, and performance overview. The stock is currently trading at 304.00 EUR, up 2.01%, with detailed valuation measures and comparisons to similar biotechnology companies.
- Published
- 8 Aug 2026 10:12
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 2 consolidated
EarningsFinanceFinancial MarketsLife Sciences
08Aug 2026
ArchivedPositive tone
ONC|Beigene Ltd|Price:359.030|Chg%:+10.760
This article provides a comprehensive stock analysis of Beigene Ltd (ONC), highlighting its strong fundamentals, high growth potential, and relatively fair valuation within the Biotechnology & Medical Research industry. It notes high institutional ownership and recent "Buy" ratings from aโฆ
Article detailsHistorical record
This article provides a comprehensive stock analysis of Beigene Ltd (ONC), highlighting its strong fundamentals, high growth potential, and relatively fair valuation within the Biotechnology & Medical Research industry. It notes high institutional ownership and recent "Buy" ratings from analysts. The analysis also covers key strengths like leading industry revenue and a turnaround to profitability, alongside risks such as being overvalued, and details the methodology behind TradingKey's stock scoring system.
- Published
- 8 Aug 2026 03:09
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
EarningsFinancial MarketsLife Sciences
07Aug 2026
ArchivedPositive tone
Beigene Ltd (ONC) Earnings Forecast: Future EPS & Revenue Growth Estimates
Article detailsHistorical record
- Published
- 7 Aug 2026 12:13
- Catalyst
- Earnings
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Provider matches checked
Provider mentions not used in the score
A news provider linked these stories to ONC, but the headline and available text are not mainly about BeiGene, Ltd.. They are kept here for transparency and do not affect the score, confidence, history or wider market totals.
Provider mentions are kept separate
Open the list to see which provider matches were checked and left out of ONC sentiment.
Open provider mentionsHow the page works
How to read the score
It describes the weighted balance of qualifying headlines. A score of 50 can mean balanced news or that there is not enough evidence; the status label explains which.
Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme. This is a rule-based evidence measure, not a calibrated probability.
Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.
It measures news already published. It is not a forecast, recommendation or price target.